$Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib$

Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib

Abstract The fms-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib is indicated for relapsed or refractory (R/R) FLT3-mutated acute myeloid leukemia (AML), based on its observed superior response and survival outcomes compared with salvage chemotherapy (SC). Frontline use of FLT3 tyrosine kinase...

Full description

Bibliographic Details
Main Authors:	Alexander E. Perl, Naoko Hosono, Pau Montesinos, Nikolai Podoltsev, Giovanni Martinelli, Nicki Panoskaltsis, Christian Recher, Catherine C. Smith, Mark J. Levis, Stephen Strickland, Christoph Röllig, Marco Groß-Langenhoff, Wen-Chien Chou, Je-Hwan Lee, Hisayuki Yokoyama, Nahla Hasabou, Qiaoyang Lu, Ramon V. Tiu, Jessica K. Altman
Format:	Article
Language:	English
Published:	Nature Publishing Group 2022-05-01
Series:	Blood Cancer Journal
Online Access:	https://doi.org/10.1038/s41408-022-00677-7

Similar Items

The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation–positive relapsed/refractory acute myeloid leukemia
by: Jessica K. Altman, et al.
Published: (2021-02-01)

Post‐stem cell transplant maintenance in FLT3mut acute myeloid leukemia – A retrospective analysis: Outcomes are improved with midostaurin but not with gilteritinib
by: Karam Ashouri, et al.
Published: (2024-04-01)

Midostaurin shapes macroclonal and microclonal evolution of FLT3-mutated acute myeloid leukemia
by: Romane Joudinaud, et al.
Published: (2025-01-01)

Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
by: Juanjuan Zhao, et al.
Published: (2019-09-01)

Sorafenib maintenance after allogeneic stem cell transplantation in patients with FLT3+ AML receiving midostaurin during induction and consolidation: a retrospective analysis
by: Giuseppe Sapienza, et al.
Published: (2024-09-01)

Unveiling unexpected adverse events: post-marketing safety surveillance of gilteritinib and midostaurin from the FDA Adverse Event Reporting database
by: Tingting Jiang, et al.
Published: (2025-01-01)

Correction to: Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
by: Juanjuan Zhao, et al.
Published: (2019-10-01)

P554: GILTERITINIB VERSUS SALVAGE CHEMOTHERAPY FOR RELAPSED/REFRACTORY FLT3-MUTATED ACUTE MYELOID LEUKEMIA: A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL TRIAL IN ASIA
by: J. Wang, et al.
Published: (2022-06-01)

Case report: Rechallenge with gilteritinib after acute pancreatitis in FLT3-positive AML
by: Taner TAN, et al.
Published: (2025-01-01)

Experience with FLT3 Inhibitor Midostaurin in Newly Diagnosed Acute Myeloid Leukemia Patients
by: Mehmet Baysal, et al.
Published: (2021-03-01)

P454: VENETOCLAX AND GILTERITINIB SYNERGIZE IN FLT3 WILDTYPE ACUTE MYELOID LEUKEMIA BY SUPPRESSION OF MCL-1 VIA COMBINED AXL AND FLT3 TARGETING
by: C. Schmidt, et al.
Published: (2022-06-01)

Regression of leukemia cutis with gilteritinib in a case of FLT3-positive acute myeloid leukemia
by: Andrea Duminuco, et al.
Published: (2022-09-01)

Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia
by: Andoni Garitano-Trojaola, et al.
Published: (2021-06-01)

P514: V-FAST MASTER TRIAL: PRELIMINARY RESULTS OF TREATMENT WITH CPX-351 PLUS MIDOSTAURIN IN ADULTS WITH NEWLY DIAGNOSED FLT3-MUTATED ACUTE MYELOID LEUKEMIA
by: J. McCloskey, et al.
Published: (2022-06-01)

Effective treatment with Gilteritinib-based regimens for FLT3-mutant extramedullary relapse in acute promyelocytic leukemia
by: Chun-xiao Hou, et al.
Published: (2024-12-01)

Erythroid differentiation of myeloblast induced by gilteritinib in relapsed FLT3-ITD–positive acute myeloid leukemia
by: Hyun Don Yun, et al.
Published: (2019-11-01)

Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia
by: Yvyin Zhang, et al.
Published: (2023-01-01)

Petromurin C Induces Protective Autophagy and Apoptosis in FLT3-ITD-Positive AML: Synergy with Gilteritinib
by: You Na Ha, et al.
Published: (2020-01-01)

Therapeutic Management of Patients with FLT3 + Acute Myeloid Leukemia: Case Reports and Focus on Gilteritinib Monotherapy
by: Bocchia M, et al.
Published: (2022-04-01)

MDM2- and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin
by: Katja Seipel, et al.
Published: (2018-11-01)

Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin
by: Frank G. Rücker, et al.
Published: (2024-12-01)

The FLT3 Y842D mutation may be highly sensitive to midostaurin: a case report
by: Shujiao He, et al.
Published: (2022-05-01)

Combined anti-leukemic effect of gilteritinib and GSK-J4 in FLT3-ITD+ acute myeloid leukemia
by: Qi Zhou, et al.
Published: (2025-02-01)

Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function
by: Denise Wolleschak, et al.
Published: (2014-06-01)

Efficacy and toxicity of midostaurin with idarubicin and cytarabine induction in <i>FLT3</I>-mutated acute myeloid leukemia
by: Julia S. Lee, et al.
Published: (2023-06-01)

Gilteritinib as treatment for extra-medullary relapse of FLT3-ITD acute myeloid leukemia FLT3-ITD, after allogeneic haematopoietic stem cell transplantation
by: R. Iannotta, et al.
Published: (2022-01-01)

Complete morphologic response to gilteritinib in ALK-rearranged acute myeloid leukemia
by: Jacob J. Adashek, et al.
Published: (2024-09-01)

P575: GILTERITINIB MAINTENANCE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR FLT3 MUTATED ACUTE MYELOID LEUKEMIA
by: Andrius Žučenka, et al.
Published: (2023-08-01)

The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML
by: Xinan Qiao, et al.
Published: (2021-06-01)

P531: MIDOSTAURIN PLUS 7 + 3 OR QUIZARTINIB PLUS 7 + 3 IN FLT3-ITD MUTATED AML
by: Mar Tormo, et al.
Published: (2023-08-01)

Gilteritinib as Bridging and Posttransplant Maintenance for Relapsed Acute Myeloid Leukemia with FLT3-ITD Mutation Accompanied by Extramedullary Disease in Elderly
by: Masuho Saburi, et al.
Published: (2023-01-01)

Phosphoproteomics predict response to midostaurin plus chemotherapy in independent cohorts of FLT3-mutated acute myeloid leukaemiaResearch in context
by: Weronika E. Borek, et al.
Published: (2024-10-01)

P523: MIDOSTAURIN PLUS INTENSIVE CHEMOTHERAPY IN FLT3 MUTATED AML. “REAL LIFE” DATA VERSUS THE RATIFY STUDY
by: A. De La Fuente, et al.
Published: (2022-06-01)

Combination of midostaurin and ATRA exerts dose-dependent dual effects on acute myeloid leukemia cells with wild type FLT3
by: Hao Lu, et al.
Published: (2022-07-01)

MIDOSTAURIN ADDED TO CYTOSINE ARABINOSIDE PLUS IDARUBICIN (“7+3”) IN NEWLY DIAGNOSED FLT3-MUTATED ACUTE MYELOID LEUKEMIA
by: P Barreto, et al.
Published: (2021-10-01)

Emergence of Natural Killer Cell Large Granular Lymphocytes during Gilteritinib Treatment in Acute Myeloid Leukemia with FLT3-ITD Mutation
by: Shintaro Izumi, et al.
Published: (2020-09-01)

Posaconazole and midostaurin in patients with FLT3‐mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study
by: Pierantonio Menna, et al.
Published: (2023-10-01)

P1319: TREATMENT WITH MIDOSTAURIN AND OTHER FLT3 TARGETING INHIBITORS IS ASSOCIATED WITH AN INCREASED RISK OF CARDIOVASCULAR ADVERSE EVENTS IN PATIENTS WITH FLT3 MUTATED AML WHO UNDERWENT ALLOGENEIC HCT
by: Anjali Cremer, et al.
Published: (2023-08-01)

P569: GILTERITINIB AND QUIZARTINIB IN RELAPSED/REFRACTORY (R/R) ACUTE MYELOBLASTIC LEUKEMIA (AML) WITH FLT3 MUTATIONS: A REAL-LIFE EFFECTIVENESS AND SAFETY STUDY
by: D. Quintela, et al.
Published: (2022-06-01)

Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and <i>KIT</i> and/or <i>FLT3</i>- ITD mutations: results of the SAL MIDOKIT trial
by: Leo Ruhnke, et al.
Published: (2023-02-01)